Introduction: Trigeminal schwannomas are benign tumors arising from the Schwann cells of the trigeminal nerve sheath, accounting for 5–8% of all intracranial schwannomas (2025, Neurosurgery). Because of their slow growth and well-defined margins, the overall prognosis is favorable.

I. Biological Characteristics and Prognosis

A domestic multicenter clinical study found that among benign tumor patients receiving standardized treatment, the 10-year postoperative survival rate can exceed 90%. However, approximately 5–10% of tumors may undergo malignant transformation or display invasive growth — making pathological examination an indispensable step following diagnosis, with dedicated testing required to exclude malignancy.

II. Factors Affecting Life Expectancy

(I) The Dual Impact of Tumor Location and Volume

Tumor location directly determines the difficulty of treatment. Tumors arising in the middle cranial fossa (approximately 40% of cases) benefit from relatively straightforward anatomy, and the gross total resection (GTR) rate reaches 85%. By contrast, dumbbell-type tumors spanning the middle and posterior cranial fossae (35% of cases) are in close proximity to critical structures such as the cavernous sinus and brainstem; here, the GTR rate falls to 68%. With regard to tumor volume, when the maximum diameter exceeds 3 cm, the risk of postoperative cranial nerve injury is 23% higher than for smaller tumors — underscoring the importance of detecting tumors early, while they are still small.

(II) The Critical Role of Extent of Resection

Complete surgical resection is the key determinant of long-term survival. A 2024 global study published in the Journal of Neurosurgery found that the 5-year recurrence-free survival rate was 91% in patients who underwent GTR, compared with only 58% in those who had partial resection. In recent years, domestic neurosurgical teams have introduced a combined microsurgery and neuroendoscopy technique, raising the GTR rate for dumbbell-type tumors from 65% to 82% and correspondingly reducing the 10-year recurrence rate to 9% — a substantial improvement in patient outcomes.

(III) The Warning Significance of Malignant Potential and Molecular Features

Although the majority of these tumors are benign (WHO grade I), approximately 1.7% may undergo malignant transformation into malignant peripheral nerve sheath tumors (WHO grade III–IV). These patients require adjuvant radiotherapy postoperatively, and their 5-year survival rate is approximately 30% lower than that of patients with benign tumors. Molecular analysis has shown that patients carrying NF2 gene mutations are at higher risk of recurrence or malignant transformation; postoperative genetic screening has therefore become a routine component of management for high-risk individuals.

III. Surgical Treatment

(I) Precise Identification of Surgical Indications

When surgery is necessary: Prompt surgical intervention is indicated when patients develop neurological deficits — such as facial numbness, diplopia, or masticatory weakness — or when the tumor causes hydrocephalus or demonstrates progressive growth (more than 2 mm per year).

When surgery may be deferred: Small, asymptomatic tumors (under 1.5 cm) may be managed with regular surveillance, with MRI every 6–12 months. If the tumor remains stable without progression, intervention can be withheld.

(II) Surgical Approach Selection and Comparative Outcomes

Different tumor locations require individualized surgical approaches:

Middle cranial fossa approach: For tumors confined to the middle cranial fossa; GTR rate 85%, cranial nerve preservation rate 92%.

Retrosigmoid approach: For posterior cranial fossa tumors; GTR rate 78%, cranial nerve preservation rate 88%.

Combined approach: For dumbbell-type tumors; GTR rate 68%, cranial nerve preservation rate 80%.

In recent years, the adoption of neuronavigation has enabled dumbbell-type tumors that previously required staged procedures to be resected in a single operation, reducing operative time by 30% and cutting the postoperative complication rate from 15% to 7%. The widespread use of intraoperative neurophysiological monitoring has further raised the trigeminal nerve branch preservation rate to 89%.

(III) Refined Management of Postoperative Complications

Common postoperative complications include facial sensory loss (approximately 35%), diplopia (18%), and masticatory weakness (12%). Through intraoperative nerve sheath dissection and preservation techniques, the rate of permanent sensory disturbance has been reduced from 25% to 11%. For patients who develop postoperative hydrocephalus, ventriculoperitoneal shunting provides effective symptom relief in 90% of cases.

IV. Non-Surgical Treatment

(I) The Role and Boundaries of Stereotactic Radiosurgery (SRS)

SRS is appropriate for elderly patients who cannot tolerate surgery, as well as for postoperative residual or recurrent tumors. Following Gamma Knife treatment, the tumor control rate reaches 85%, though the risk of radiation-induced cerebral edema — occurring in approximately 10% of cases — warrants careful attention. A 2025 study published in a Cancer sub-journal reported a 10-year progression-free survival rate of 72% following SRS, slightly lower than that achieved with complete surgical resection.

(II) Current Status and Exploration of Pharmacological Treatment

No drug currently exists that can directly inhibit tumor growth in this setting. For bilateral trigeminal schwannomas associated with NF2 gene mutations, targeted agents such as mTOR inhibitors (e.g., everolimus) are undergoing clinical evaluation, though their definitive efficacy requires further investigation.

V. Postoperative Follow-Up and Recurrence

(I) A Stratified Follow-Up Framework

Benign tumors with complete resection: MRI every 3 months during the first postoperative year, then annually for 5 years.

Partial resection or SRS: MRI every 6 months; if tumor volume increases by more than 20%, timely intervention is required.

Malignant tumors or confirmed gene mutation carriers: Combined MRI and PET-CT every 3–6 months for comprehensive surveillance of recurrence or metastasis.

(II) Management of Recurrent Tumors

Re-operation is the preferred approach for recurrent tumors, with a GTR rate of approximately 60% — lower than primary surgery owing to scar adhesion from the initial procedure. For patients who are not candidates for repeat surgery, fractionated radiotherapy or proton therapy serves as an alternative, with a 5-year local control rate of 65% (2024, Neuroradiology).

VI. Common Misconceptions

(I) "It's benign — observation is sufficient and no intervention is needed"

This is incorrect. Approximately 30% of asymptomatic tumors progress to symptomatic disease within 5 years, and compression of critical structures can lead to irreversible neurological injury. Clinical follow-up data show that for patients whose tumors enlarge during the observation period, surgical difficulty increases by 40% compared with early intervention, and the postoperative recovery period is twice as long.

(II) "Surgery is too risky and will likely cause facial palsy"

The data tell a different story. Modern microsurgical techniques have substantially reduced the risk of nerve injury. Intraoperative neurophysiological monitoring enables real-time localization of trigeminal nerve branches, with facial nerve preservation rates exceeding 88% (2025, Journal of Clinical Neuroscience). The rate of permanent facial palsy is below 5%; the majority of cases involve transient edema that improves progressively with structured rehabilitation.

(III) "Radiotherapy can replace surgery as the first-line treatment"

This requires careful qualification. Radiotherapy is appropriate only for specific patient groups and cannot achieve definitive tumor eradication. Complete surgical resection remains the only potentially curative intervention, and carries a lower risk of long-term complications — such as radiation-induced brain necrosis — than radiotherapy. For younger patients, surgery is the preferred option to avoid the potential long-term effects of radiation on brain tissue.

Frequently Asked Questions

1. How long can patients with trigeminal schwannoma live?

Following standardized treatment of a benign tumor, life expectancy approaches that of the general population. The 10-year survival rate after complete resection exceeds 90%. In untreated patients or those who undergo partial resection, the 5-year survival rate is approximately 60%. Malignant tumors carry a worse prognosis, with a 5-year survival rate of approximately 40–50%.

2. Is trigeminal schwannoma treatable?

In most cases, yes. Benign tumors have a low recurrence rate after complete surgical resection. Malignant tumors require a multimodal approach combining surgery and radiotherapy. Among patients who receive an early diagnosis and appropriate treatment, over 80% are able to return to a normal quality of life.

3. Is trigeminal schwannoma a form of brain cancer?

No. Trigeminal schwannoma is a benign nerve sheath tumor. Malignant transformation is exceedingly rare, occurring in fewer than 2% of cases, and must be confirmed by pathological examination.

4. Is surgery always necessary for trigeminal schwannoma?

Not necessarily. Small, asymptomatic tumors may be closely observed. However, when neurological deficits develop, the tumor enlarges, or hydrocephalus occurs, surgery is the treatment of choice. Surgical resection effectively relieves compression, reduces the risk of malignant transformation, and significantly improves the patient's quality of life.

Reference: https://www.incsg.com/sanchaqiaoliu/5658.html